A5019787106- Antibiotic Resistance in Bacteria
- Antibiotic Use and Resistance
- Pharmaceutical Economics and Policy
- Escherichia coli research studies
- Biosimilars and Bioanalytical Methods
- Vibrio bacteria research studies
- Healthcare cost, quality, practices
- Pharmaceutical Practices and Patient Outcomes
- Pharmaceutical and Antibiotic Environmental Impacts
- Clostridium difficile and Clostridium perfringens research
- Infection Control in Healthcare
- Healthcare Systems and Practices
- Bacteriophages and microbial interactions
- Zoonotic diseases and public health
- Animal Disease Management and Epidemiology
- Evolution and Genetic Dynamics
- Viral Infections and Outbreaks Research
- Pharmaceutical Quality and Counterfeiting
Université de Limoges
2017-2025
Inserm
2017-2023
CNR de la Résistance aux Antibiotiques
2016-2020
Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques
2020
Building the European Antimicrobial Resistance Surveillance network in Veterinary medicine (EARS-Vet) was proposed to strengthen One Health antimicrobial resistance (AMR) surveillance approach.
Abstract Background Infection prevention and control (IPC) is one of the most cost-effective interventions against antimicrobial resistance (AMR). Yet, IPC knowledge gaps often receive little prominence in AMR research agendas. In this article, we construct priorities, order to draw attention these critical needs. Methods We developed a 4-step framework identify from literature (narrative review). These were then translated into priorities sent two groups European experts for validation...
Antibiotic innovation is in serious jeopardy as companies continue to abandon the market due a lack of profitability. Novel antibiotics must be used sparingly hinder spread resistance, but small cannot survive on revenues that do not cover operational costs. When these either go bankrupt or move onto other therapeutic areas, may no longer accessible patients. Although significant research efforts have detailed incentives stimulate antibiotic innovation, little attention has been paid...
Prominent reports have assessed the challenges to antibiotic innovation and recommended implementing “pull” incentives, i.e., mechanisms that give increased predictable revenues for important, marketed antibiotics. We set out understand countries’ perceptions of these recommendations, through frank anonymous dialogue. In 2019 2020, we performed in-depth interviews with national policymakers resistance experts in 13 countries (ten European three non-European) a total 73 individuals 27...
Mots clés : antibiorésistance, une seule santé, bactériologiste
La Covid-19 nous a rappelé les dangers liés aux zoonoses et invite à repenser notre vision de la Santé. Dans un monde où hommes, animaux écosystèmes sont liés, seule une approche collective basée sur le partages des savoirs expertises, dite Une Seule Santé ou One Health, peut espérer endiguer menaces sanitaires venir. Parmi ces menaces, l’antibiorésistance serait responsable, chaque année, plus 30 000 décès en Europe. Ces 20 dernières années, su fédérer acteurs santé humaine, animale...